• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

AbbVie's Botox patent lawsuit is 'very unlikely to derail' Revance's...

cafead

Administrator
Staff member
  • cafead   Oct 11, 2021 at 09:52: PM
via For a small company seeking to market a rival to a dominant brand, a patent lawsuit from a global pharma giant would seem to be a cause for concern. But Revance has a good chance of beating back AbbVie's recent patent case, one team of analysts figures.

article source